Gilead Sciences: Why Slowing Hep-C Sales Don’t Matter
February 05, 2016 at 11:29 AM EST
Another day, another analyst pounding the table on Gilead Sciences ( GILD ), which has tumbled 15% so far this year. In a report released last night, Leerink's Geoffrey Porges initiated Gilead Sciences at Buy with a $125 price target. He explains why:
